Susan Chubinskaya, Ph.D., Vice-Provost, Faculty Affairs and Professor, Osteoarthritis Research, Department of Pediatrics, Rush University Medical Center, was inducted into the American Institute for Medical and Biological Engineering (AIMBE) College of Fellows.
Representing the top two percent of medical and biological engineers in the country, the College of Fellows comprises medical and biological engineering professionals in the fields of academia, industry and government.
Chubinskaya was nominated, reviewed and elected by peers and members of the College of Fellows for developing fundamental knowledge regarding cartilage pathobiology and therapeutic approaches to tissue regeneration and for excellent professional leadership and service. A formal induction ceremony for the 174 inductees will be held during AIMBE’s 2021 Annual Event, to be held virtually, on March 26.
Chubinskaya joins the College of Fellows representing Rush along with Joshua Jacobs, M.D., Chairperson, Department of Orthopedic Surgery, and Professor, Department of Orthopedic Surgery, who was inducted in 2000, and Gunnar B.J. Andersson, M.D., Ph.D., Professor and Chairman Emeritus, Department of Orthopedic Surgery, who was inducted in 1995.
AIMBE Fellows are regularly recognized for their contributions in teaching, research, and innovation. AIMBE Fellows have been awarded the Nobel Prize, the Presidential Medal of Science and the Presidential Medal of Technology and Innovation. Many also are members of the National Academy of Engineering, National Academy of Medicine and National Academy of Sciences.
AIMBE’s mission is to recognize excellence in, and advocate for, the fields of medical and biological engineering in order to advance society. Since 1991, AIMBE’s College of Fellows has led the way for technological growth and advancement in the fields of medical and biological engineering. AIMBE Fellows have helped revolutionize medicine and related fields to enhance and extend the lives of people all over the world. They have successfully advocated for public policies that have enabled researchers and business-makers to further the interests of engineers, teachers, scientists, clinical practitioners and, ultimately, patients.
